evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/geneAliases/7,gene/geneAliases/8,gene/geneAliases/9,gene/geneAliases/10,gene/geneAliases/11,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract
16568,GENE_BACKGROUND,,"KMT2A encodes the histone methyltransferase MLL1, an epigenetic modulator that methylates lysine residue 4 on the tail of histone H3 (H3K4). Methylation of H3K4 leads to increased genome accessibility, recruitment of transcriptional complexes, and activation of gene expression (PMID: 25998713). MLL1 is crucial for embryogenesis and normal hematopoiesis by stimulating expression of several important developmental genes including the homeobox (Hox) genes (PMID: 24213472). Chromosomal translocations involving MLL1 that result in gain-of-function fusion proteins have been identified in pediatric and adult acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) and are overrepresented in therapy-related AML. Though MLL1 has a diverse group of fusion partners in leukemia, the most common MLL1 recombination partners include AF4, AF9, and ENL, which are proteins that interact with transcriptional elongation machinery (PMID: 28701730). MLL1 fusion proteins disrupt the normal activity of hematopoietic stem cells and the normal chromatin state, leading to activation of oncogenic signaling pathways (PMID: 16862118). In addition, loss-of-function mutations in MLL1 have been identified in solid tumors including bladder, stomach and endometrial cancers (PMID: 21822268, 23636398). DOT1L inhibitors, which are currently being tested in clinical trials, have been shown to have activity against MLL1-rearranged leukemias (PMID: 21741597, 21741596).",,2017-10-04,,4297,KMT2A,lysine methyltransferase 2A,False,ENST00000534358,NM_001197104.1,MLL-AF9,MLL1,TRX1,HTRX1,TET1-MLL,ALL-1,MLL/GAS7,MLL,MLL1A,CXXC7,HRX,WDSTS,True,21822268,Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder.,Nature genetics,2018-08-07T20:11:00,43,9,875-8,Gui Y et al,doi: 10.1038/ng.907,,0001-08-07,,16862118,Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.,Nature,2018-08-17T20:06:00,442,7104,818-22,Krivtsov AV et al,,,0001-08-17,,21741596,Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.,Cancer cell,2018-07-12T20:11:00,20,True,53-65,Daigle SR et al,doi: 10.1016/j.ccr.2011.06.009,,0001-07-12,,24213472,Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.,Cancers,2018-09-10T20:12:00,4,3,904-44,Ballabio E et al,doi: 10.3390/cancers4030904,,0001-09-10,,23636398,Integrated genomic characterization of endometrial carcinoma.,Nature,2018-05-02T20:13:00,497,7447,67-73,Cancer Genome Atlas Research Network. et al,doi: 10.1038/nature12113,,0001-05-02,,21741597,MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.,Cancer cell,2018-07-12T20:11:00,20,True,66-78,Bernt KM et al,doi: 10.1016/j.ccr.2011.06.010,,0001-07-12,,28701730,The MLL recombinome of acute leukemias in 2017.,Leukemia,2018-07-13T20:17:00,,,,Meyer C et al,doi: 10.1038/leu.2017.213,,0001-07-13,,25998713,Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.,Nature reviews. Cancer,2018-06-01T20:15:00,15,6,334-46,Rao RC et al,doi: 10.1038/nrc3929,,0001-06-01,
16567,GENE_SUMMARY,,KMT2A encodes a histone methyltransferase and transcriptional coactivator that regulates gene expression during development and hematopoesis.,,2017-04-27,,4297,KMT2A,lysine methyltransferase 2A,False,ENST00000534358,NM_001197104.1,MLL-AF9,MLL1,TRX1,HTRX1,TET1-MLL,ALL-1,MLL/GAS7,MLL,MLL1A,CXXC7,HRX,WDSTS,True,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
